The PNOC001 phase II single-arm trial sought to estimate progression-free survival (PFS) associated with everolimus therapy for progressive/recurrent pediatric low-grade glioma (pLGG) on the basis of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway activation as measured by phosphorylated-ribosomal protein S6 and to identify prognostic and predictive biomarkers.
Journal of Clinical Oncology PNOC001: Phase II Study of Everolimus For Recurrent or Progressive Low-Grade Gliomas in Children
Previous
Previous
Neuro-Oncology Rational combination platform trial design for children and young adults with diffuse midline glioma
Next
Next